Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACR-2316 in Advanced Solid Tumors
NCT06667141Phase 2Recruiting
- Sponsor
- Acrivon Therapeutics, Inc.
- Start
- Oct 2024
- Primary completion
- Aug 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ACR-2316 in solid tumor, sponsored by Acrivon Therapeutics, Inc.. Started Oct 2024; status: recruiting.
02
Drugs
ACR-2316
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT06667141.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06667141.